Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 12/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.40 |
| ▸ | PNP | P00491 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21385659 | 0.89 | ADA (0.46) | HPRT1PNPLMNA | |
| SCHEMBL21625880 | 0.88 | ADORA2A (0.56) | HPRT1ADORA2AADORA2BADORA1PNP | |
| SCHEMBL7812368 | 0.84 | HPRT1 (0.47) | HPRT1PNPLMNA | |
| SCHEMBL11243652 | 0.84 | HPRT1 (0.49) | HPRT1PNPLMNA | |
| SCHEMBL784333 | 0.82 | ADORA2A (0.51) | HPRT1ADORA2AADORA2BADORA1PNP | |
| SCHEMBL21385661 | 0.81 | HPRT1 (0.55) | HPRT1PNPMEN1LMNAKMT2A | |
| SCHEMBL20681481 | 0.80 | HPRT1 (0.49) | HPRT1ADORA2BPNPLMNA | |
| SCHEMBL18877201 | 0.80 | HPRT1 (0.49) | HPRT1ADORA2BPNPLMNA | |
| SCHEMBL18479940 | 0.80 | HPRT1 (0.52) | HPRT1SLC29A1PNPMEN1LMNA | |
| SCHEMBL22364035 | 0.80 | HPRT1 (0.49) | HPRT1ADORA2BPNPLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220251135-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | BEONE MEDICINES I GMBH (CH) | 2022-08-11 | — | — | US | disclosed |
| US-20210206796-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2021-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206796-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | HPRT1 266/4885ADORA2A 70/4885ADORA2B 148/4885 |
| US-20220251135-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | STING1, CGAS, MAVS | HPRT1 110/4885ADORA2A 122/4885ADORA2B 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.